SOURCE: Atlan International Holdings

June 04, 2007 01:53 ET

Atlan Completes Developmental Plan for AT 103-ED

PRINCETON, NJ--(Marketwire - June 4, 2007) - Atlan International Holdings Corp. (FRANKFURT: QV8) (PINKSHEETS: ATLI), a company which is a global development, marketing, sales and acquisition firm with subsidiaries that develop, design and market pharmaceuticals, biotechnology, bio-pharmaceuticals, alternative medicines & nutraceuticals, announced today that its subsidiary Atlan Pharma Inc. completed and approved the developmental plan for their first pharmaceutical product, AT 103-ED, that is being developed for an indication of erectile dysfunction. The company is in the process of selecting contract houses for various activities related to this product development. The first to be initiated is the formulation development that will utilize the platform technology licensed by Atlan for which the US and PCT patents are pending. Later in 2007, the company is planning to have a meeting with the FDA to discuss the agency's requirements for IND submission and then clinical development of the product.

Wieslaw Bochenek, MD, PhD, company Chief Scientific Officer, stated: "This is an important milestone for the Company and its new drug development process. We are excited on the opportunity ahead of us. Our new technology will allow for creation of formulations that will offer ease of use and an excellent safety profile with negligible or minimal systemic effects. Wound healing and fungal skin and nail infections are major unresolved medical problems that still await more efficacious methods of treatment and which affect large numbers of people."

About Atlan International Holdings Corp. (FRANKFURT: QV8) (PINKSHEETS: ATLI); Atlan is a global development, marketing, sales and acquisition firm with subsidiaries that develop, design and market pharmaceuticals, biotechnology, bio-pharmaceuticals, alternative medicines & nutraceutical, and alternative energy & processes. Atlan's international relationships and strengths allow it to offer products for co-development and to independently market & co-market multiple products.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.

Contact Information